Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587011 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Complications in anterior cruciate ligament reconstruction.
J Clin Orthop Trauma
February 2025
Department of Traumatology, Knee and Arthroscopy Unit, Clínica Alemana, Universidad Del Desarrollo, Santiago, Chile.
Anterior cruciate ligament reconstruction (ACLR), despite its effectiveness in restoring knee stability and function, can have associated morbidity. The most frequent complications are technical errors, which have been described during graft harvesting, tunnel placement or graft fixation. The most serious complications are neurovascular injuries, arthrofibrosis and infections.
View Article and Find Full Text PDFUse of Oral and Intravenous Tranexamic Acid in Total Knee Arthroplasty and Total Hip Arthroplasty Procedures.
Cureus
December 2024
General Orthopedics, Midwest Bone and Joint Center, Macon, USA.
Introduction: Tranexamic acid (TXA) is an antifibrinolytic drug commonly used in total knee arthroplasty (TKA). Intravenous (IV) and topical TXA therapy have been extensively studied and shown to reduce blood loss, length of hospital stay, and blood transfusion rates following TKA. Despite the extensive literature regarding IV and topical TXA in orthopedics, there is a current dearth of studies analyzing oral usage.
View Article and Find Full Text PDFTwo-stage revision anterior cruciate ligament reconstruction reduces failure risk but leads to lesser clinical outcomes than single-stage revision after primary anterior cruciate ligament graft failure: a retrospective cohort study.
Knee Surg Relat Res
January 2025
IU Health Physicians Orthopedics & Sports Medicine, 1801 N Senate Ave, Indianapolis, IN, 46202, USA.
Background: There are no studies that compare the outcomes and complications of single-versus two-stage revision anterior cruciate ligament reconstruction (ACLR) after primary ACLR failure. This purpose of this study is to examine clinical and functional outcomes and complications associated with single and two-stage revision ACLR after primary ACLR failure.
Methods: All patients who underwent single or two-stage revision ACLR after primary ACLR failure between 2012 and 2021 with a minimum of a 2 year follow-up were included.
Treatment of posterolateral tibial plateau fractures through the articular line approach.
BMC Musculoskelet Disord
January 2025
Department of Orthopedics, Lishui Central Hospital, Zhejiang, 323000, China.
Background: Posterolateral tibial plateau fractures pose significant challenges for orthopedic surgeons due to the anatomical risks associated with the posterolateral approach. Despite numerous surgical techniques available, there lacks a consensus on the optimal approach.
Methods: Articular line incision approach was employed on 12 patients suffering from posterolateral tibial plateau fractures.
Rethinking Repeat Two-Stage Knee Exchange Arthroplasty: Outcomes, Risks, and Decision-Making.
J Arthroplasty
January 2025
Department of Orthopaedic Surgery, Chang Gung Memorial Hospital (CGMH), No. 5 Fu-Hsing Street, Kweishan, Taoyuan, Taiwan; Bone and Joint Research Center, Chang Gung Memorial Hospital (CGMH), No. 5 Fu-Hsing Street, Kweishan, Taoyuan, Taiwan; College of Medicine, Chang Gung University (CGU), 259 Wen-Hwa 1st Road, Kweishan, Taoyuan, Taiwan. Electronic address:
Background: Chronic periprosthetic joint infection (PJI) presents a major challenge in knee arthroplasty, with varying success rates reported for two-stage exchange arthroplasty (EA) and a lack of consensus on managing failures from such procedures. This study evaluated repeat two-stage EA outcomes for knee PJI after initial treatment failure to identify the risk factors for reimplantation unsuitability and reinfection.
Methods: We analyzed 114 patients who underwent repeat EA for chronic knee PJI between 2010 and 2018.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!